The present invention relates to a method for expressing, water-solubilizing, and purifying protein by using a calsequestrin-tag (CSQ-tag). Provided are: a recombinant expression vector containing a CSQ-tag and a target protein; a host cell transformed using the recombinant expression vector; and a method for expressing and purifying a target protein by using a CSQ tag. The present invention uses CSQ-tags to increase the expression of proteins that are widely used in pharmaceuticals and cosmetics, and allows the proteins to be easily separated by calcium, and thus is expected to be able to lower the cost of protein materials and protein pharmaceuticals.

Provision of a chimeric antigen receptor (CAR) comprising a disialoganglioside (GD2)-binding domain which comprises •a) a heavy chain variable region (VH) having complementarity determining regions (CDRs) with the following sequences: •b) a light chain variable region (VL) having CDRs with the following sequences: T cells expressing such a CAR are useful in the treatment of some cancers.

The present invention relates to polypeptide variants of human fibroblast growth factor 21 (FGF21) and fusion molecules thereof, as well as to nucleic acid molecules encoding the same. It further relates to their use as medicaments, in particular for the treatment of obesity, overweight, metabolic syndrome, diabetes mellitus, hyperglycemia, dyslipidemia, non-alcoholic steatohepatitis (NASH) and/or atherosclerosis.

The purpose of the present invention is to provide a method for producing a peptide that interacts with a lipid bilayer, and a lipid-bilayer-penetrating peptide obtained through the method. Provided is a lipid-bilayer-penetrating peptide constructed from 10 to 100 amino acids, the peptide having an amino acid sequence that penetrates the lipid bilayer at the C-terminal, and having an amino acid sequence with at least six contiguous arginine at the N-terminal. Also provided is a construct for producing a lipid-bilayer-penetrating peptide, the construct including, from the 5′ end toward the 3′ end, a tag region 1, a region 1 for incorporating a fluorescent protein gene sequence, a fluorescent protein gene region, a region 2 for incorporating a fluorescent protein gene sequence, a random region, and a stop codon region, and the construct being such that the random region has the aforementioned sequences.

The disclosure, in some aspects, provides antigen-specific amino acid sequences for tick-borne relapsing fever Borrelia species.

The present invention relates inter alia to a polynucleotide or viral vector encoding a variant of BPIFB4 (Bactericidal/Permeability Increasing protein family B, member 4) protein and to their use for the treatment of pathologies involving impairment of nitric oxide signalling.

The present invention relates to an anti-IL-6 antibody, a pharmaceutical composition or a kit comprising the same, and uses thereof.

The present disclosure provides fusion proteins comprising a nanobody and a glycan modifying enzyme. Also provided herein are methods of glycosylating a protein and methods of removing a sugar from a protein. Further provided in the present disclosure are methods of treating and/or diagnosing diseases. Also provided herein are kits, polynucleotides, vectors, and cells.

The invention relates to PGT121-germline-targeting designs, trimer stabilization designs, combinations of those two, trimers designed with modified surfaces helpful for immunization regimens, other trimer modifications and on development of trimer nanoparticles and methods of making and using the same.

The present invention relates, in part, to chimeric proteins that find use in various immunotherapies. Particularly, the present invention provides targeted therapeutic agents that modulate the immune system for the treatment of diseases such as cancer.